FTC Says Ivax Misconstrues Hatch-Waxman Rules
The U.S. Food and Drug Administration should reject Ivax Pharmaceutical Inc.'s "flawed" petition for a 180-day marketing exclusivity period for its generic version of Merck & Co.'s cholesterol-lowering drug Zocor, the...To view the full article, register now.
Already a subscriber? Click here to view full article